• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Tharimmune, Inc. - Common Stock (NQ: THAR )

    3.400 +0.080 (+2.41%)
    Streaming Delayed Price Updated: 3:06 PM EDT, Jul 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,026
    Open 3.270
    Bid (Size) 2.940 (3)
    Ask (Size) 3.400 (7)
    Prev. Close 3.320
    Today's Range 3.270 - 3.400
    52wk Range 0.1434 - 5.480
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Tharimmune Announces $2.08 Million Private Placement
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga

    Performance

    YTD
    +573.40%
    +573.40%
    1 Month
    -34.24%
    -34.24%
    3 Month
    +661.99%
    +661.99%
    6 Month
    +596.72%
    +596.72%
    1 Year
    +1444.75%
    +1444.75%

    More News

    Read More
    Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Why Tharimmune (THAR) Shares Are Moving
    Via Benzinga
    THAR Stock Earnings: Tharimmune Reported Results for Q4 2023
    Via InvestorPlace
    Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
    Via ACCESSWIRE
    Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
    Via ACCESSWIRE
    Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Why Tharimmune (THAR) Shares Are Getting Hammered
    Via Benzinga
    Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
    Via ACCESSWIRE
    Tharimmune to Present at 2024 BIO International Convention
    Via ACCESSWIRE
    Why Is Verastem (VSTM) Stock Down 62% Today?
    Via InvestorPlace
    Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?
    Via InvestorPlace
    Why Is Tharimmune (THAR) Stock Moving Today?
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Tharimmune Announces 1-for-15 Reverse Stock Split
    Via ACCESSWIRE
    Tharimmune, Inc. (NASDAQ: THAR) Featured in Coverage of the EF Hutton Annual Global Conference
    Via Investor Brand Network
    Tharimmune To Participate in Two Upcoming Investor Conferences in May
    Via ACCESSWIRE
    Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
    Via ACCESSWIRE
    Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
    Via ACCESSWIRE
    Tharimmune's Oral 'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver Disease
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
    Via ACCESSWIRE
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.